Responses
Clinical and epidemiological research
Extended report
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
Compose a Response to This Article
Other responses
No responses have been published for this article.